Dataset Information

Sexual Dimorphism of Plasma Proteomes in Human Calcific Aortic Valve Stenosis

ABSTRACT: Females are underrepresented in studies of calcific aortic valve stenosis (CAVS), leading to delay in timely intervention and increased mortality. Histopathology demonstrates female CAVS presents with decreased valvular calcification but increased fibrosis and severity of symptoms. CAVS plasma samples (n=20 females, n=30 males) were analyzed for circulating sex-specific biomarkers via LC-MS/MS.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Aortic Valve Stenosis

SUBMITTER: Cassandra Clift

LAB HEAD: Elena Aikawa

PROVIDER: PXD064030 | Pride | 2025-11-24

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	02_FB_B15_B25-Pooled-Plasma.msf	Msf
	02_FB_B3-Pooled-Plasma-1.msf	Msf
	02_FB_B3_B4_B6_B7_B15_B25-Pooled-Plasma.mzML	Mzml
	02_FB_B3_B4_B6_B7_B15_B25-Pooled-Plasma.mzid	Mzid
	02_FB_B3_B4_B6_B7_B15_B25-Pooled-Plasma.pdResult	Other

Items per page:

1 - 5 of 67

Publications

Sexual Dimorphism of Plasma and Tissue Proteomes in Human Calcific Aortic Valve Stenosis Pathogenesis-Brief Report.

Clift Cassandra L CL Blaser Mark C MC Bartoli-Leonard Francesca F Schlotter Florian F Higashi Hideyuki H Kuraoka Shiori S Kasai Taku T Turner Mandy E ME Pham Tan T Perez Katelyn A KA Robson Simon C SC Body Simon C SC Muehlschlegel Jochen D JD Aikawa Masanori M Singh Sasha A SA Aikawa Elena E

Arteriosclerosis, thrombosis, and vascular biology 20250814 10

<h4>Background</h4>Calcific aortic valve stenosis is a global clinical burden, impacting around 2% of the population over 65 years of age. No pharmacotherapeutics exist, with surgical repair and transcatheter valve replacement being the only intervention. Females are underrepresented in studies of calcific aortic valve stenosis, leading to delay in timely intervention and increased mortality. Histopathology demonstrates female calcific aortic valve stenosis presents with decreased valvular calci ...[more]

PMID: 40808650

Similar Datasets

Project description:Introduction: Retinopathy of prematurity (ROP) with early vessel loss (Phase I) followed by uncontrolled vessel growth (Phase II) causes visual impairment in premature infants. Although supplementation with n-3 docosahexaenoic acid (DHA) alone has mixed results to prevent ROP, combined supplementation with DHA and n-6 arachidonic acid (ARA) in early postnatal life reduces severe ROP by 50% (Mega Donna Mega study). The underlying mechanisms are unknown. Objectives: To evaluate protective effects and mechanism of combined dietary n-3 DHA and n-6 ARA in a neonatal mouse model of Phase I ROP. Methods: In the Mega Donna Mega study, most preterm infants had early postnatal hyperglycemia episodes, a strong risk factor for severe ROP. We used a neonatal mouse model of hyperglycemia-induced suppression of retinal vascular development (Phase I ROP). Dams were fed diets enriched with 3%DHA or 1%DHA+2%ARA. In P10 milk-fed pups, we assessed retinal vascularization, and proteome, and fatty acid profiles in retina, retinal pigment epithelium (RPE) complex and plasma. In vivo, oligomycin A, a mitochondrial ATP synthase inhibitor, was used to assess mitochondrial participation in the combined lipid protective effects. Results: In 201 (97.6%) of 206 randomized infants there was at least one elevated glucose measurement during the first 14 days. In a neonatal mouse model of hyperglycemia-induced suppression of vascular development, maternal DHA+ARA vs. DHA diet promoted pup retinal vessel growth. Fatty acid profiling confirmed lipid changes in pup plasma and RPE complex in accord with DHA and ARA levels in the maternal diets. Proteomic retinal analysis revealed increased abundance of proteins related to mitochondrial respiration and glucose metabolism in the combined diet. Inhibition of mitochondrial ATP synthase negated the protective effects of the combined diet on retinal vascularization. Conclusion: Combined DHA+ARA oral supplementation in the early postnatal period protects against Phase I ROP in mouse neonates, through enhanced retinal metabolism suggesting the potential of balanced lipid supplementation for preventing ROP.